» Articles » PMID: 27622058

Suppressive Effects of Tumor Cell-derived 5'-deoxy-5'-methylthioadenosine on Human T Cells

Abstract

The immunosuppressive tumor microenvironment represents one of the main obstacles for immunotherapy of cancer. The tumor milieu is among others shaped by tumor metabolites such as 5'-deoxy-5'-methylthioadenosine (MTA). Increased intratumoral MTA levels result from a lack of the MTA-catabolizing enzyme methylthioadenosine phosphorylase (MTAP) in tumor cells and are found in various tumor entities. Here, we demonstrate that MTA suppresses proliferation, activation, differentiation, and effector function of antigen-specific T cells without eliciting cell death. Conversely, if MTA is added to highly activated T cells, MTA exerts cytotoxic effects on T cells. We identified the Akt pathway, a critical signal pathway for T cell activation, as a target of MTA, while, for example, p38 remained unaffected. Next, we provide evidence that MTA exerts its immunosuppressive effects by interfering with protein methylation in T cells. To confirm the relevance of the suppressive effects of exogenously added MTA on human T cells, we used an MTAP-deficient tumor cell-line that was stably transfected with the MTAP-coding sequence. We observed that T cells stimulated with MTAP-transfected tumor cells revealed a higher proliferative capacity compared to T cells stimulated with Mock-transfected cells. In conclusion, our findings reveal a novel immune evasion strategy of human tumor cells that could be of interest for therapeutic targeting.

Citing Articles

The Tumor Metabolite 5'-Deoxy-5'Methylthioadenosine (MTA) Inhibits Maturation and T Cell-Stimulating Capacity of Dendritic Cells.

Brummer C, Singer K, Henrich F, Peter K, Strobl C, Neueder B Cells. 2025; 13(24.

PMID: 39768204 PMC: 11727219. DOI: 10.3390/cells13242114.


MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Gounder M, Johnson M, Heist R, Shapiro G, Postel-Vinay S, Wilson F Nat Commun. 2025; 16(1):423.

PMID: 39762248 PMC: 11704051. DOI: 10.1038/s41467-024-55316-5.


Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment.

Zheng Y, Xu R, Chen X, Lu Y, Zheng J, Lin Y Cell Death Dis. 2024; 15(10):775.

PMID: 39461979 PMC: 11513100. DOI: 10.1038/s41419-024-07122-6.


Oxylipins and metabolites from pyroptotic cells act as promoters of tissue repair.

Mehrotra P, Maschalidi S, Boeckaerts L, Maueroder C, Tixeira R, Pinney J Nature. 2024; 631(8019):207-215.

PMID: 38926576 DOI: 10.1038/s41586-024-07585-9.


Quantitative proteomics analysis reveals possible anticancer mechanisms of 5'-deoxy-5'-methylthioadenosine in cholangiocarcinoma cells.

Kerdkumthong K, Nanarong S, Roytrakul S, Pitakpornpreecha T, Tantimetta P, Runsaeng P PLoS One. 2024; 19(6):e0306060.

PMID: 38923999 PMC: 11206958. DOI: 10.1371/journal.pone.0306060.


References
1.
Bertino J, Waud W, Parker W, Lubin M . Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biol Ther. 2011; 11(7):627-32. PMC: 3084968. DOI: 10.4161/cbt.11.7.14948. View

2.
Kirovski G, Stevens A, Czech B, Dettmer K, Weiss T, Wild P . Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA). Am J Pathol. 2011; 178(3):1145-52. PMC: 3069916. DOI: 10.1016/j.ajpath.2010.11.059. View

3.
Nyakern M, Cappellini A, Mantovani I, Martelli A . Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther. 2006; 5(6):1559-70. DOI: 10.1158/1535-7163.MCT-06-0076. View

4.
Blanchet F, Schurter B, Acuto O . Protein arginine methylation in lymphocyte signaling. Curr Opin Immunol. 2006; 18(3):321-8. DOI: 10.1016/j.coi.2006.03.001. View

5.
Ohta A, Gorelik E, Prasad S, Ronchese F, Lukashev D, Wong M . A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006; 103(35):13132-7. PMC: 1559765. DOI: 10.1073/pnas.0605251103. View